← Home / Aktis Oncology, Inc. (AKTS)
Stock Analysis
Aktis Oncology, Inc. (AKTS)
AKTS
AKTS · Market data
22.07 -4.04%
Track AKTS in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when AKTS price is:
52W Range Position
40%
LOWMIDHIGH
Trend
Mixed
Momentum
Neutral
Updated: 2026-08-02 16:45 UTC
WOI Investment Thesis
Mixed
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Insufficient / Negative
✓
Price Structure
Mixed
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
23.89
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
11
●
Financial Results
HIGH
Aktis Oncology Reports Financial Results and Business Highlights For First Quarter 2026
• Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments • Initiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); expect preliminary data in 2027 • Announced AKY-2519 clinical imaging and dosimetry data presen...
8-K Filing • SEC EDGAR
What's Driving AKTS?
📈 Technical recovery is improving
Momentum is Neutral. Watch 23.89 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 20.60 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
39.3
◎
How to read this setup
From a roadmap perspective, the setup is boxed by support near 20.60 and resistance around 23.89. A move through resistance would be needed to materially improve the chart, while a break of support would keep the pressure side dominant.
Price Chart
AKTS — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$1.2B
Company size
EV
$807.0M
Debt-adjusted value
P/B
2.3
Balanced
EV/Sales
250.1
Very high
EV/EBIT
-35.5
Not meaningful
P/FCF
-45.2
Not meaningful
FCF Yield
-2.21%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Negative
≈
Cash Flow
Mixed
⚖
Balance Sheet
Strong
💵 Revenue
3.23M
≈ Insufficient
📈 Net Income
-18.32M
↘ Negative
🧮 EPS (Basic)
-0.38
↘ Negative
Aktis Oncology, Inc.
Related Opportunities